Opioid Addiction Clinical Trial
Official title:
Observational, Prospective Study to Evaluate Levomethadone Safety Profile and Effectiveness in Subjects Under Opioid Maintenance Treatment
Multicentre, prospective, observational, non-interventional, open- ended trial, collecting data from male and female patients aged ≥ 18 years, with a diagnosis of opioid addiction according to ICD-10 (F11.2), treated with therapeutic doses of levomethadone according to the routine medical practice.
Multicentre, prospective, observational, non-interventional, open- ended trial, collecting data from male and female patients aged ≥ 18 years, with a diagnosis of opioid addiction according to ICD-10 (F11.2), treated with therapeutic doses of levomethadone according to the routine medical practice. The study is divided in two different consecutive parts: - Part 1 [from Informed Consent form (ICF) to last data collected at V4]: patients enrolled are receiving levomethadone maintenance treatment according to clinical practice. - Part 2 (after V4 up to FU): patients are in opioid maintenance treatment with any drug (including levomethadone) according to clinical practice. The maximum duration on-study for a patient will be 405 days [from ICF signature (-30 days from V1) to FU (=360 + 15)]. This study is an open-ended trial. This means that for the enrolment and for the study, no maximum duration has been established. The study, which is a voluntary Post Authorization Safety Study (PASS), will be carried out on approximately 10 centers in Italy. The objectives are to provide further data on the safety profile after long term use and effectiveness of levomethadone, administered according Summary of Product Characteristics (SmPC) and in a real word clinical setting, in opioid-addicted patients undergoing maintenance treatment. Safety will be assessed throughout all the study and safety data will be described and analysed based on Adverse Drug Reactions and corrected QT (QTc) prolongation at 12-lead electrocardiogram (ECG), where available. The effectiveness outcomes are the evaluation of levomethadone maintenance treatment according to investigator's judgment at V4(180 days), based on different questionnaires and assessment. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04336293 -
sTMS for Substance Use-disordered Veterans
|
N/A | |
Completed |
NCT01188421 -
Medications Development for Drug Abuse Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT00499746 -
The Discriminative Effects of Tramadol in Humans
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05611749 -
Duloxetine Impact on Postoperative Pain Control and Outcomes
|
Phase 2 | |
Recruiting |
NCT04325659 -
An Innovative Intervention for OUD Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT04239235 -
Integrating Support Persons Into Recovery
|
N/A | |
Not yet recruiting |
NCT03394911 -
Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction
|
Phase 3 | |
Not yet recruiting |
NCT02282072 -
PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction
|
Phase 0 | |
Not yet recruiting |
NCT01008072 -
Ultra-rapid Opiate Detoxification Using Deep Sedation and Prior Oral Buprenorphine Preparation.
|
N/A | |
Completed |
NCT02696096 -
Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence
|
Phase 3 | |
Recruiting |
NCT05299515 -
Peer Activate: Trial of Peer-Delivered Behavioral Activation for Methadone Adherence
|
N/A | |
Recruiting |
NCT04309565 -
Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support
|
N/A | |
Completed |
NCT01873989 -
Testosterone Replacement for Male Opioid Agonist Maintained Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01590251 -
Yoga for Pain and Opioid Dependence
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02866266 -
ER/LA Opioid Surveillance for Emergency Department Visits and Hospitalizations for Overdose and Poisoning
|
N/A | |
Enrolling by invitation |
NCT02871232 -
Surveillance Monitoring of Opioid Abuse in Poison and Drug Treatment Centers
|
N/A |